Defendant
1 case as defendant.
Reckitt Benckiser Pharmaceuticals, Inc. (RPI) was a Delaware-incorporated specialty pharmaceutical company with its principal U.S. headquarters in Richmond, Virginia (Fairfax Building, 10710 Midlothian Turnpike). It was an indirect, wholly-owned subsidiary of Reckitt Benckiser Group plc (RB), the UK-listed consumer health and hygiene group headquartered in Slough, England. On 23 December 2014, RB completed a demerger of the business, which was renamed Indivior Inc. and now trades as part of Indivior PLC (LSE). The "Reckitt Benckiser Pharmaceuticals" name therefore refers to a predecessor entity; the parent RB employed roughly 40,000 people and reported revenue in the £13–14bn range. RPI's own standalone headcount and revenue are not reliably documented in public sources.
Operations. RPI developed, distributed, marketed and sold opioid-dependence treatments in the United States. Its flagship products were Suboxone (buprenorphine/naloxone) Sublingual Tablets and the later Suboxone Sublingual Film, plus Subutex (buprenorphine) tablets. It also entered development agreements for alternative delivery formats, including a naloxone nasal spray. This is an operating pharmaceutical business, not a patent-assertion entity.
Litigation posture. The tracked data shows zero cases as plaintiff and one as defendant — a purely defensive profile typical of an operating company. Its single tracked matter is a contract dispute rather than a patent infringement suit, and it is not an NPE or shell licensor. No venue clustering in plaintiff-friendly districts such as the Eastern District of Texas appears in this record.
Notable case. AntiOp, Inc. v. Reckitt Benckiser Pharmaceuticals, Inc. (E.D. Ky., No. 5:16-cv-00051, Lexington Division) is a diversity breach-of-contract action. AntiOp alleged RPI/Indivior owed a $3,000,000 milestone payment under a Development Agreement covering a naloxone nasal spray formulation; RPI (naming Indivior Inc., Indivior PLC and Scopia Capital among defendants) moved to dismiss on forum-selection and Rule 12(b)(6) grounds, and the court denied dismissal on the contract claim. Broader external context: RB and Indivior were also the subject of FTC/DOJ and state antitrust and marketing investigations concerning Suboxone "product hopping," which are separate from this tracked case.
Breach-of-contract action in which AntiOp alleged entitlement to a $3,000,000 milestone payment upon issuance of its '570 patent. The court addressed which forum governed under the agreement's forum-selection clause (S.D.N.Y. was designated). Not a patent infringement suit.